
Alector Inc (ALEC) Stock Forecast & Price Target
Alector Inc (ALEC) Analyst Ratings
Bulls say
Alector Inc. is making significant strides in its clinical trials, particularly with AL001 showing a 48% reduction in the rate of clinical progression, suggesting potential stabilization for patients with neurodegeneration. The firm’s therapeutic candidates, especially AL101, exhibit differentiated pharmacokinetics (PK) that may enhance patient compliance and reduce overall treatment costs, further strengthening its market position. With no approved disease-modifying agents currently available and a sizable patient population estimated at over 10,000 in the US and EU, Alector appears to be well-positioned to capture substantial market opportunities in treating neurodegenerative diseases.
Bears say
Alector Inc reported a net loss of $2 million, or $0.02 per share, for the fourth quarter of 2024, highlighting the company's ongoing financial challenges. The failure of the INVOKE-2 Phase 2 trial for AL002 to meet primary efficacy endpoints raises concerns regarding the viability of its neurodegenerative treatment pipeline, resulting in a significant drop of over 30% in share price during after-hours trading. Furthermore, the potential risks associated with the clinical failure of key therapies AL001 and AL002, as well as challenges in achieving regulatory approval and commercial revenue estimates, contribute to a negative outlook for the company's stock.
This aggregate rating is based on analysts' research of Alector Inc and is not a guaranteed prediction by Public.com or investment advice.
Alector Inc (ALEC) Analyst Forecast & Price Prediction
Start investing in Alector Inc (ALEC)
Order type
Buy in
Order amount
Est. shares
0 shares